Cresco Labs closes PharmaCann acquisition for US$50 million
Cresco Labs announced the closing of its acquisition of 100% of PharmaCann Penn, LLC for aggregate consideration of US$50 million.
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) said it has closed its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC for aggregate consideration of US$50 million. The company described the deal as the Transaction.